drugset / Trial / NCT07276373
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
This open-label, dose-finding, and proof of concept study will evaluate the safety, tolerability, maximum-tolerated dose (MTD) and/or optimal dose of nenocorilant when administered in combination with nivolumab in patients with advanced solid malignancies.
Timeline
- Start
- 2026-01-16
- Primary completion
- 2026-09
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nenocorilant | Small molecule | 200 mg | Oral |
| Subject | Nenocorilant | Small molecule | 300 mg | Oral |
| Subject | Nenocorilant | Small molecule | 400 mg | Oral |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |